Stoke Other Current Liab from 2010 to 2024

STOK Stock  USD 11.91  0.14  1.19%   
Stoke Therapeutics Other Current Liabilities yearly trend continues to be quite stable with very little volatility. The value of Other Current Liabilities is projected to decrease to about 8.7 M. From the period between 2010 and 2024, Stoke Therapeutics, Other Current Liabilities regression line of its data series had standard deviation of  4,063,401 and standard deviation of  4,063,401. View All Fundamentals
 
Other Current Liabilities  
First Reported
2018-03-31
Previous Quarter
12.2 M
Current Value
13.5 M
Quarterly Volatility
5.2 M
 
Covid
Check Stoke Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Stoke Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 9.2 M, Interest Income of 131.1 K or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 30.42, Dividend Yield of 0.0 or PTB Ratio of 1.52. Stoke financial statements analysis is a perfect complement when working with Stoke Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

Latest Stoke Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Stoke Therapeutics over the last few years. It is Stoke Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Stoke Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Stoke Other Current Liab Regression Statistics

Arithmetic Mean5,954,927
Geometric Mean4,862,556
Coefficient Of Variation68.24
Mean Deviation3,494,836
Median3,574,000
Standard Deviation4,063,401
Sample Variance16.5T
Range12M
R-Value0.73
Mean Square Error8.3T
R-Squared0.54
Significance0
Slope664,990
Total Sum of Squares231.2T

Stoke Other Current Liab History

20248.7 M
202311.8 M
202213.4 M
202113.2 M
20208.9 M
20193.4 M
20181.4 M

About Stoke Therapeutics Financial Statements

Stoke Therapeutics investors utilize fundamental indicators, such as Other Current Liab, to predict how Stoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Current Liabilities11.8 M8.7 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
0.328
Quarterly Revenue Growth
0.479
Return On Assets
(0.28)
Return On Equity
(0.52)
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.